Tags

Type your tag names separated by a space and hit enter

Formulation of sustained-release dosage form of verapamil hydrochloride by solid dispersion technique using Eudragit RLPO or Kollidon SR.
AAPS PharmSciTech. 2009; 10(1):27-33.AP

Abstract

The release of verapamil hydrochloride from tablets with Eudragit RLPO or Kollidon SR with different drug-to-polymer ratios were investigated with a view to develop twice-daily sustained-release dosage form by solid dispersion (SD) technique. The SDs containing Eudragit RLPO or Kollidon SR at drug-polymer ratios of 1:1, 1:2, and 1:3 with verapamil hydrochloride were developed using solvent evaporation technique. The physical mixtures of drug and both polymers were prepared by using simple mixing technique at the same ratio as solid dispersion. The physicochemical properties of solid dispersion were evaluated by using Fourier transform infrared spectroscopy (FTIR), X-ray diffraction (XRD), and differential scanning calorimetry (DSC). The study of DSC, XRD, and FTIR could not show significant interaction between verapamil HCl and Kollidon SR or Eudragit RLPO. The solid dispersions or physical mixtures were compressed to tablets. The tablets were prepared with solid dispersions containing Eudragit RLPO or Kollidon SR, with all the official requirements of tablet dosage forms fulfilled. Tablets prepared were evaluated for the release of verapamil hydrochloride over a period of 12 h in pH 6.8 phosphate buffer using US Pharmacopoeia type II dissolution apparatus. The in vitro drug release study revealed that the tablet containing Eudragit has extended the release rate for 12 h whereas the tablet containing Kollidon SR at the same concentration has extended the release rate up to 8 h. The in vitro release profile and the mathematical models indicate that release of verapamil hydrochloride can be effectively controlled from a tablet containing solid dispersions of Eudragit RLPO. The reduction of size fraction of the SD system from 200-250 to 75-125 microm had a great effect on the drug release.

Authors+Show Affiliations

Department of Pharmaceutical Technology, Royal College of Pharmacy and Health Sciences, Andhapasara Road, Berhampur, Orissa, India. pjagannath_sahoo@yahoo.co.inNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

19145487

Citation

Sahoo, J, et al. "Formulation of Sustained-release Dosage Form of Verapamil Hydrochloride By Solid Dispersion Technique Using Eudragit RLPO or Kollidon SR." AAPS PharmSciTech, vol. 10, no. 1, 2009, pp. 27-33.
Sahoo J, Murthy PN, Biswal S, et al. Formulation of sustained-release dosage form of verapamil hydrochloride by solid dispersion technique using Eudragit RLPO or Kollidon SR. AAPS PharmSciTech. 2009;10(1):27-33.
Sahoo, J., Murthy, P. N., Biswal, S., & Manik, . (2009). Formulation of sustained-release dosage form of verapamil hydrochloride by solid dispersion technique using Eudragit RLPO or Kollidon SR. AAPS PharmSciTech, 10(1), 27-33. https://doi.org/10.1208/s12249-008-9175-0
Sahoo J, et al. Formulation of Sustained-release Dosage Form of Verapamil Hydrochloride By Solid Dispersion Technique Using Eudragit RLPO or Kollidon SR. AAPS PharmSciTech. 2009;10(1):27-33. PubMed PMID: 19145487.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Formulation of sustained-release dosage form of verapamil hydrochloride by solid dispersion technique using Eudragit RLPO or Kollidon SR. AU - Sahoo,J, AU - Murthy,P N, AU - Biswal,S, AU - Manik,, Y1 - 2009/01/15/ PY - 2008/07/29/received PY - 2008/11/05/accepted PY - 2009/1/16/entrez PY - 2009/1/16/pubmed PY - 2009/6/24/medline SP - 27 EP - 33 JF - AAPS PharmSciTech JO - AAPS PharmSciTech VL - 10 IS - 1 N2 - The release of verapamil hydrochloride from tablets with Eudragit RLPO or Kollidon SR with different drug-to-polymer ratios were investigated with a view to develop twice-daily sustained-release dosage form by solid dispersion (SD) technique. The SDs containing Eudragit RLPO or Kollidon SR at drug-polymer ratios of 1:1, 1:2, and 1:3 with verapamil hydrochloride were developed using solvent evaporation technique. The physical mixtures of drug and both polymers were prepared by using simple mixing technique at the same ratio as solid dispersion. The physicochemical properties of solid dispersion were evaluated by using Fourier transform infrared spectroscopy (FTIR), X-ray diffraction (XRD), and differential scanning calorimetry (DSC). The study of DSC, XRD, and FTIR could not show significant interaction between verapamil HCl and Kollidon SR or Eudragit RLPO. The solid dispersions or physical mixtures were compressed to tablets. The tablets were prepared with solid dispersions containing Eudragit RLPO or Kollidon SR, with all the official requirements of tablet dosage forms fulfilled. Tablets prepared were evaluated for the release of verapamil hydrochloride over a period of 12 h in pH 6.8 phosphate buffer using US Pharmacopoeia type II dissolution apparatus. The in vitro drug release study revealed that the tablet containing Eudragit has extended the release rate for 12 h whereas the tablet containing Kollidon SR at the same concentration has extended the release rate up to 8 h. The in vitro release profile and the mathematical models indicate that release of verapamil hydrochloride can be effectively controlled from a tablet containing solid dispersions of Eudragit RLPO. The reduction of size fraction of the SD system from 200-250 to 75-125 microm had a great effect on the drug release. SN - 1530-9932 UR - https://www.unboundmedicine.com/medline/citation/19145487/Formulation_of_sustained_release_dosage_form_of_verapamil_hydrochloride_by_solid_dispersion_technique_using_Eudragit_RLPO_or_Kollidon_SR_ L2 - https://dx.doi.org/10.1208/s12249-008-9175-0 DB - PRIME DP - Unbound Medicine ER -